Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.
Tanda M, Yamamoto K, Hori T, Nishiguchi H, Yagi M, Shimizu M, Konishi T, Ozaki T, Yoshioka N, Tachihara M, Ito T, Ikushima S, Omura T, Yano I.
Tanda M, et al. Among authors: nishiguchi h.
Anticancer Res. 2023 Apr;43(4):1775-1783. doi: 10.21873/anticanres.16331.
Anticancer Res. 2023.
PMID: 36974789